Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients - PACE-CME

Lessons from ISARREACT about which antiplatelet agent to choose in ACS patients

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
ESC 2019
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
- Prof. François Mach, MD
Betablocker use associated with reduced mortality in HFrEF patients >80 years
Betablocker use associated with reduced mortality in HFrEF patients >80 years
ESC 2019
Betablocker use associated with reduced mortality in HFrEF patients >80 years
- Gianluigi Savarese, MD
Sex-related differences in ACS patients
Sex-related differences in ACS patients
ESC 2019
Sex-related differences in ACS patients
- Sanne Peters, PhD
NP metabolism associated with clinical outcomes in HF
NP metabolism associated with clinical outcomes in HF
ESC 2019
NP metabolism associated with clinical outcomes in HF
- Frank Gommans, MD, PhD